The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
A major push to sharpen the future of cancer treatment is underway
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The Abbreviated New Drug Application with FDA covers multiple strengths of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
Three-day programme equips CSIR researchers with advanced AI tools, molecular docking insights, and biomolecular simulation expertise
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
